Diagnostic marker signature for esophageal cancer from transcriptome analysis

Tumor Biology

Volumn 37, Issue 5, 2016, Pages 6349-6358

  Warnecke Eberz, Ute ^a   Metzger, Ralf ^b   Hölscher, Arnulf H ^a   Drebber, Uta ^a   Bollschweiler, Elfriede ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Caritasklinikum Saarbrücken   (Germany)

Author keywords

Diagnostic marker; DNA microarrays; Esophageal cancer; Gene expression profiling

Indexed keywords

INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; SOMATOMEDIN BINDING PROTEIN 2; STROMELYSIN; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CCL4 GENE; CHST2 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; COL4A2 GENE; CONTROLLED STUDY; CTHRC1 GENE; DIAGNOSTIC MARKER; DIAGNOSTIC VALUE; DOWN REGULATION; EMILIN2 GENE; EMR2 GENE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IGFBP2 GENE; IGFBP7 GENE; KCNJ8 GENE; LILRB2 GENE; LPCAT1 GENE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MMP1 GENE; MMP12 GENE; MMP3 GENE; PLA2G7 GENE; PRAME GENE; PRIORITY JOURNAL; SNX10 GENE; TRANSCRIPTOMICS; TREM2 GENE; UPREGULATION; VALIDATION PROCESS; WDR72 GENE; AGED; BIOSYNTHESIS; DNA MICROARRAY; ESOPHAGEAL NEOPLASMS; GENETICS; ISOLATION AND PURIFICATION; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRANSCRIPTOME;

EID: 84948980633     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4400-4     Document Type: Article

References (34)

1. Pennathur A, Gibson MK, Jobe BA. Oesophageal carcinoma. Lancet. 2013;381:400–12. doi:10.1016/S0140-6736(12)60643-6.
2. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92:549–55.
3. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–62.
4. Lepage C, Drouillard A, Jouve JL, Faivre J. Epidemiology and risk factors for esophageal adenocarcinoma. Dig Liver Dis. 2013;45:625–9.
5. Hölscher AH, Bollschweiler E, Schröder W, Metzger R, Gutschow C, Drebber U. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esopageal cancer. Ann Surg. 2011;254:802–7.
6. Warnecke-Eberz U, Hoffmann A, Luebke T, Prenzel K, Metzger R, Heitmann M, et al. Surviving mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol. 2007;95:51–4.
7. Zhang J, Zhu Z, Liu Y, Jin X, Xu Z, Yu Q, et al. Diagnostic value of multiple tumor markers for patients with esophageal carcinoma. PLoS One. 2015;10(2):e0116951. doi:10.1371/journal.pone.0116951.
8. Metzger R, Heukamp L, Drebber U, Bollschweiler E, Hölscher AH, Warnecke-Eberz U. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics. 2010;11:1105–13.
9. Warnecke-Eberz U, Metzger R, Bollschweiler E, Baldus SE, Müller RP, Dienes HP, et al. TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2011;11:55–64.
10. Käll L, Storey JD, Noble WS. QVALITY: non-parametric estimation of q-values and posterior error probabilities. Bioinformatics. 2009;25:964–6.
11. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45:478–86.
12. Gao Y-B, Chen Z-L, Li J-G, Hu X-D, Shi X-J, Sun ZM, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097–102.
13. Kim YW, Bae SM, Kim YW, Park DC, Lee KH, Liu HB, et al. Target-based molecular signature characteristics of cervical adenocarcinoma and squamous cell carcinoma. Int J Oncol. 2013;43:539–47.
14. Du Q, Yan W, Burgon VH, Hewitt SM, Wang L, Hu N, et al. Validation of esophageal squamous cell carcinoma candidate genes from high-throughput transcriptomic studies. Am J Cancer Res. 2013;3:402–10.
15. An H, Chandra V, Piraino B, Borges L, Geczy C, McNeil HP, et al. Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol. 2010;37:1596–606.
16. El-sharkawi F, El Sabah M, Hassan Z, Khaled H. The biochemical value of urinary metalloproteinases 3 and 9 in diagnosis and prognosis of bladder cancer in Egypt. J Biomed Sci. 2014;21:72.
17. Fu JH, Wang LQ, Li T, Ma GJ. RNA-sequencing based identification of crucial genes for esophageal squamous cell carcinoma. J Cancer Res Ther. 2015;11:420–5.
18. Su H, Hu N, Yang HH, Wang C, Takikita M, Wang Q-H, et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Clin Cancer Res. 2011;17:2955–66.
19. Uraoka N, Oue N, Sakamotot N, Sentani K, Oo HZ, Naito Y, et al. NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression. Cancer Sci. 2014;105:134–40.
20. Li X, Qu L, Zhong Y, Zhao Y, Chen H, Daru L. Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: meta-analysis. J Cancer Res Clin Oncol. 2013;139:1433–47.
21. Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis. 2014;25:2519–24.
22. Chen TY, Hwang TL, Lin CY, Lin TN, Lai HY, Tsai PW, et al. EMR2 receptor ligation modulates cytokine secretion profiles and cell survival of lipopolysaccharide-treated neutrophils. Chang Gung Med J. 2011;34:468–77.
23. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cast JA, Navarro G, San Jose-Eneriz E, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007;31:521–8.
24. Szczepanski MJ, Whiteside TL, Szczepanski MJ, Whiteside TL. Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? Biomark Med. 2013;7:575–8.
25. Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of miroRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39:665–72.
26. Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, et al. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014;12:3310–8.
27. Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen-Laakso T, Virtanen J, et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget. 2011;2:1176–90.
28. Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 2013;70:2657–75.
29. Fung KYC, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompela C, et al. Blood-based protein biomarker panel for the detection of colorectal cancer. Plos One. 2015. doi:10.1371/journal.pone.0120425.
30. Tessema M, Yingling CM, Liu Y, Tellez CS, Van Neste L, Baylin S, et al. Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis. 2014;35:1248–57.
31. Yu C-J, Wang CL, Wang CI, Chen CD, Dan YM, Wu CC, et al. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J Proteome Res. 2011;10:4671–82.
32. Marastoni S, Andreuzzi E, Paulitti A, Colladel R, Pelicani R, Todaro F, et al. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration. J Pathol. 2014;232:391–404.
33. Mann B, Madera M, Klouckova I, Mechref Y, Dobrolecki LE, Hickey RJ, et al. A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis. 2010;31:1833–41.
34. Mares J, Szakacsova M, Soukup V, Duskova J, Horinek A, Babjuk M. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results. Neoplasma. 2013;60:295–301.